Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This was a retrospective registry-based study utilizing data collected in association with clinical care of patients. All data was stored in electronic health records at Terveystalo data base, and no patients were contacted for the study.
Patients initiating erenumab treatment between 20.9.2018 - 15.10. 2019, and data on sick leave days, diagnoses and health care visits as well as medications based on prescriptions were assessed.
Following time frames for analyses of sick leaves and health care utilization in patients on erenumab treatment and in controls were reported:
Follow-up analyses: For cases (erenumab) with occupational healthcare, a minimum of 12 months on erenumab treatment was required for the analysis of sick leaves and visits
Pre erenumab: Follow-up data before index (defined as the first reimbursement decision/prescription for erenumab, or initiation of erenumab injections (before reimbursement approval)) from the Terveystalo database of those with consent
Post erenumab: Follow-up data after index, from the Terveystalo database of those with consent
Time frames for comparison (sick leaves and visits): One year before index vs. >12 months erenumab after index, One year before index vs. 6-12 months of erenumab after index (patient years), sensitivity analysis
Time frames for comparison (medications): 12 months before index vs. 12 months post follow-up
Controls (triptan treated migraine patients): Corresponding time frames as in cases.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Erenumab responder patients | Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses |
| |
| Migraine controls | Age and gender matched migraine patients on triptan medication, excluding those on botulinum toxin, erenumab and fremanezumab to benchmark the level of HCRU, sick leaves, and medication patterns |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Erenumab | Other | Patients who met the responder definition of two or more erenumab prescriptions with no evidence of switch to other CGRPi were included in the main analyses |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of sick leave days (headache) | Sick leaves included migraine or head-ache related registered sick leave days at Terveystalo in the occupational healthcare cohort and controls. | throughout the study, approximately 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Change in number of sick leave days (all cause) | Sick leaves included all registered sick leave days at Terveystalo in the occupational healthcare cohort and controls. | throughout the study, approximately 2 years |
| Change in number of healthcare visits (head-ache related) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
None
Not provided
Not provided
Adult patients on erenumab treatment
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigative Site | East Hanover | New Jersey | 07936-1080 | United States |
Not provided
| Label | URL |
|---|---|
| Results for CAMG334AFI03 from the Novartis Clinical Trials Results Database | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D008881 | Migraine Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000605816 | erenumab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Number of headache related healthcare visits were reported. |
| throughout the study, approximately 2 years |
| Change in number of healthcare visits (all cause) | Number of healthcare visits were reported. | throughout the study, approximately 2 years |
| Medication patterns: Number of patients receiving medications of interest | The number of patients receiving medications of interest in erenumab treated patients in migraine patient controls were reported. | throughout the study, approximately 2 years |
| D009422 | Nervous System Diseases |